31 completed, 5 terminated, 1 active not recruiting, 1 withdrawn. 21 Phase 1, 19 Phase 2, 2 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 21 | Completed 16, Terminated 4, Withdrawn 1 |
| Phase 2 | 19 | Completed 17, Active not recruiting 1, Terminated 1 |
| Not applicable | 2 | Completed 2 |
Follow Recurrent Salivary Gland Cancer: new trials by email Literature Review of Recurrent Salivary Gland Cancer trials Research Report on Recurrent Salivary Gland Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma 9-ING-41, Carboplatin, Pembrolizumab - Salivary Gland Cancer, Recurrent Salivary Gland Cancer | Phase 2 | Active not recruiting | Glenn J. Hanna | 32 | 2021-09-17 | 2026-08-07 |
| Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck sorafenib tosylate, cisplatin, docetaxel - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 1 | Completed | Ohio State University Comprehensive Cancer Center | 3 | 2014-04-14 | 2018-05-24 |
| Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy acetylcysteine, placebo, quality-of-life assessment - Mucositis, Oral Complications | Phase 2 | Completed | Mayo Clinic | 34 | 2014-04-01 | 2019-04-30 |
| Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection vorinostat, diagnostic laboratory biomarker analysis, pharmacological study - HIV Infection, Recurrent Anal Cancer | Phase 1 | Terminated | AIDS Malignancy Consortium | 17 | 2013-11-01 | 2020-07-29 |
| PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer PI3K inhibitor BKM120, cetuximab - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 1 / Phase 2 | Completed | University of Chicago | 12 | 2013-05-01 | 2021-10-05 |
| Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer carboplatin, paclitaxel albumin-stabilized nanoparticle formulation, fluorouracil - Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx | Phase 1 | Completed | University of Chicago | 48 | 2013-03-26 | 2024-07-31 |
| 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy 18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2 - Adult Giant Cell Glioblastoma, Adult Glioblastoma | Phase 1 / Phase 2 | Completed | Sanjiv Sam Gambhir | 25 | 2013-03-04 | 2019-10-03 |
| Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer eribulin mesylate - Recurrent Salivary Gland Cancer, Stage IVA Salivary Gland Cancer | Phase 2 | Completed | University of Washington | 29 | 2012-05-08 | 2018-09-28 |
| Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer talactoferrin, laboratory biomarker analysis - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 1 | Terminated | Stanford University | 4 | 2012-05-01 | 2016-08-02 |
| TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck TLR8 agonist VTX-2337, cetuximab, laboratory biomarker analysis - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 1 | Completed | University of Washington | 13 | 2011-06-01 | 2015-03-05 |
| Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy everolimus, erlotinib hydrochloride, biopsy - Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer | Phase 1 | Withdrawn | Fox Chase Cancer Center | 2011-04-01 | 2023-04-04 | |
| Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer cetuximab, paclitaxel, carboplatin - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 2 | Completed | Fox Chase Cancer Center | 24 | 2011-02-16 | 2018-02-26 |
| L-lysine in Treating Oral Mucositis in Patients Undergoing Radiation Therapy With or Without Chemotherapy For Head and Neck Cancer quality-of-life assessment, management of therapy complications, L-lysine - Mucositis, Oral Complications of Chemotherapy | Not applicable | Completed | University of Washington | 10 | 2010-09-01 | 2013-05-17 |
| Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck lapatinib ditosylate, capecitabine - Head and Neck Cancer, Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma | Phase 2 | Completed | Abramson Cancer Center at Penn Medicine | 44 | 2009-10-01 | 2020-03-19 |
| Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab cetuximab, placebo, sorafenib tosylate - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 2 | Completed | National Cancer Institute (NCI) | 55 | 2009-07-01 | 2026-03-10 |
| Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer everolimus, cetuximab, pharmacological study - Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip | Phase 1 | Completed | Fox Chase Cancer Center | 12 | 2008-11-01 | 2012-07-11 |
| Sunitinib, Cetuximab, and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck sunitinib malate, pharmacological study, 3-dimensional conformal radiation therapy - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 1 | Terminated | National Cancer Institute (NCI) | 36 | 2008-07-01 | 2013-07-02 |
| Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer dasatinib, pharmacological study, laboratory biomarker analysis - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 2 | Completed | National Cancer Institute (NCI) | 15 | 2007-07-01 | 2014-10-01 |
| Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer bevacizumab, placebo, magnetic resonance imaging - Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma | Phase 2 | Completed | National Cancer Institute (NCI) | 11 | 2007-06-01 | 2014-05-09 |
| Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer cetuximab, erlotinib hydrochloride, laboratory biomarker analysis - Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum | Phase 1 | Completed | National Cancer Institute (NCI) | 43 | 2007-01-01 | 2015-09-30 |
Showing 20 of 38. Sign in to see all of them.
Salivary Gland Neoplasms (38) · Squamous Cell Carcinoma of Head and Neck (31) · Tongue Neoplasms (18) · Esthesioneuroblastoma, Olfactory (11) · Carcinoma, Non-Small-Cell Lung (9) · Colonic Neoplasms (9) · Breast Neoplasms (7) · Pancreatic Neoplasms (7) · Rectal Neoplasms (7) · Stomach Neoplasms (6) · Anus Neoplasms (5) · Breast Neoplasms, Male (5) · Carcinoma, Hepatocellular (5) · Carcinoma, Ovarian Epithelial (5) · Esophageal Neoplasms (5)
Mouth Diseases (38) · Neoplasms by Site (38) · Salivary Gland Diseases (38) · Stomatognathic Diseases (38) · Head and Neck Neoplasms (37) · Mouth Neoplasms (37) · Neoplasms (37) · Carcinoma (34) · Neoplasms by Histologic Type (34) · Neoplasms, Glandular and Epithelial (34) · Carcinoma, Squamous Cell (30) · Tongue Diseases (18) · Neoplasms, Germ Cell and Embryonal (13) · Neoplasms, Nerve Tissue (13) · Neuroectodermal Tumors (13)
Cetuximab (8) · Erlotinib Hydrochloride (6) · Carboplatin (4) · Bevacizumab (3) · Lapatinib (3) · N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine (3) · Sorafenib (3) · Taxes (3) · Docetaxel (2) · Everolimus (2) · Fluorouracil (2) · Hydroxyurea (2) · Paclitaxel (2) · Radiation (2) · Radiotherapy (2)
National Cancer Institute (NCI) (22) · Fox Chase Cancer Center (3) · University of Washington (3) · University of Chicago (2) · AIDS Malignancy Consortium (1) · Abramson Cancer Center at Penn Medicine (1) · Glenn J. Hanna (1) · Mayo Clinic (1) · Ohio State University Comprehensive Cancer Center (1) · Roswell Park Cancer Institute (1) · Sanjiv Sam Gambhir (1) · Stanford University (1)
United States (36) · Canada (2)
Barbara Burtness (2) · Alain Mita (1) · Antonius Miller (1) · Athanassios Argiris (1) · Christopher Thomas (1) · Corey Langer (1) · David Gustin (1) · David Solit (1) · Eric Kraut (1) · Eric Winquist (1) · Everett Vokes (1) · Glenn J Hanna, MD (1) · Hassan Arshad (1) · Heather Wakelee (1) · Jessica Bauman, MD (1)
PMID 23868427, PMID 25057165, PMID 25965900, PMID 26062933, PMID 26611425, PMID 26928328, PMID 30850872, PMID 31405750, PMID 35429391, PMID 35945244, PMID 40166973
U10CA032102 (3), N01CM62201 (2), N01CM62202 (2), N01CM62203 (2), P30CA016672 (2), U01CA076576 (2), U10CA021115 (2), N01CM00100 (1), N01CM17102 (1), P30CA006927 (1), P30CA015083 (1), P30CA015704 (1), P30CA044579 (1), P30CA054174 (1), P30CA068485 (1)